ReviewMetabolic brain disease2026
The relationship between gut microbiota and neurodegenerative diseases: a genetic and epigenetic perspective.
Review in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gut microbiota as a modulator of HDAC: insights into Alzheimer's disease treatment.Pharmacological reports : PR · 2026Review
- Clinical application of fecal microbiota transplantation and its influencing factors.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gut microbiota (GM) is a complex and dynamic structure that can have a wide range of effects on human health. Studies in recent years have shown that microbiota is not only related to the gastrointestinal tract (GIT) but also to the immune and endocrine systems. It causes various effects on host physiology, especially through genetic and epigenetic mechanisms. It shows that microbiota-derived metabolites can play a role in the development of neurological diseases by changing gene expression. In this review article, the relationship between GM and neurodegenerative diseases (NDs) is explained in terms of genetics and epigenetics. In terms of the gut–brain axis (GBA); the role of systems such as short-chain fatty acids (SCFA), vagus nerve, inflammatory responses and intestinal permeability in the pathogenesis of NDs such as Alzheimer's (AD), Parkinson's (PD), Huntington's (HD) and Multiple Sclerosis (MS) is discussed. In addition, experimental studies have drawn attention to the effects of changes in microbiota on neuroinflammation and cognitive impairment. In terms of treatment strategies; Probiotics, prebiotics, synbiotics, fecal microbiota transplantation (FMT) and nutritional interventions targeting microbiota seem to be promising strategies. However, the fact that microbiota structure varies between individuals indicates that studies in this area should be conducted in a more personalized manner. This article aims to provide a basis for future research by approaching the relationship between microbiota and NDs in a holistic manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.